Hannover Medical School Researcher Releases New Study Findings on Liver Function (Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort).

A recent study conducted at Hannover Medical School compared the real-world effectiveness of lenvatinib (LEN) to atezolizumab/bevacizumab (AZ/BV) in treating hepatocellular carcinoma (HCC) patients. The study included 412 patients across 18 university hospitals in Europe and found that both treatments are viable first-line options for HCC. However, patients treated with AZ/BV had a longer median progression-free survival, but also a higher risk of hepatic decompensation in cases of impaired baseline liver function. The study emphasizes the importance of careful monitoring and the need for future trials to distinguish between different liver diseases. [Extracted from the article]